dc.contributorCentro de Reprodução Humana Prof. Franco Junior
dc.contributorUniversidade Estadual Paulista (Unesp)
dc.contributorUniversidade de Santo Amaro
dc.contributorCentro de Reprodução Humana Prof. Franco Junior, Ribeirão Preto
dc.date.accessioned2014-05-27T11:22:00Z
dc.date.accessioned2022-10-05T18:03:26Z
dc.date.available2014-05-27T11:22:00Z
dc.date.available2022-10-05T18:03:26Z
dc.date.created2014-05-27T11:22:00Z
dc.date.issued2006-10-01
dc.identifierJornal Brasileiro de Reproducao Assistida, v. 10, n. 4, p. 9-16, 2006.
dc.identifier1517-5693
dc.identifier1518-0557
dc.identifierhttp://hdl.handle.net/11449/69156
dc.identifier2-s2.0-33847306557
dc.identifier.urihttp://repositorioslatinoamericanos.uchile.cl/handle/2250/3918632
dc.description.abstractThe purpose of this investigation was to verify the efficacy of recombinant LH supplementation for controlled ovarian stimulation in GnRH-antagonist protocol for assisted reproductive technologies cycles. Search strategies included on-line surveys of databases from 1990 to 2006. In this review and meta-analysis, the observed advantages for the LH supplementation protocol were a higher serum estradiol levels on the day of hCG administration and a higher number of mature oocytes. However, there were no differences observed in the total amount of r-FSH administered, days of stimulation, number of oocyte retrieved, the clinical pregnancy rate per oocyte retrieval, the implantation rate and miscarriage rate. This result demonstrates that the association of r-LH with r-FSH may prevent any decrease in estradiol after antagonist administration and a significant higher number of mature oocytes was obtained. Nevertheless, additional randomized controlled trials are needed confirm these observations.
dc.languagepor
dc.relationJornal Brasileiro de Reproducao Assistida
dc.relation0,282
dc.rightsAcesso aberto
dc.sourceScopus
dc.subjectGnRH antagonist
dc.subjectOvarian stimulation
dc.subjectRecombinant FSH
dc.subjectRecombinant LH
dc.subjectcetrorelix
dc.subjectchorionic gonadotropin
dc.subjectestradiol
dc.subjectethinylestradiol
dc.subjectethinylestradiol plus gestodene
dc.subjectgonadorelin antagonist
dc.subjectlevonorgestrel
dc.subjectoral contraceptive agent
dc.subjectrecombinant follitropin
dc.subjectrecombinant luteinizing hormone
dc.subjectclinical trial
dc.subjectcombination chemotherapy
dc.subjectdata base
dc.subjectdrug dose regimen
dc.subjectdrug efficacy
dc.subjectdrug mechanism
dc.subjectestradiol blood level
dc.subjecthormone substitution
dc.subjecthuman
dc.subjectlow drug dose
dc.subjectmeta analysis
dc.subjectmonotherapy
dc.subjectoocyte
dc.subjectovary function
dc.subjectpregnancy rate
dc.subjectspontaneous abortion
dc.subjectsystematic review
dc.titleO emprego de hormônio luteinizante recombinante associado ao hormônio folículo-estimulante recombinante nos protocolos de estimulação ovariana com antagonista do GnRH
dc.typeArtigo


Este ítem pertenece a la siguiente institución